Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from bioAffinity Technologies, Inc. ( (BIAF) ).
On February 10, 2026, bioAffinity Technologies, Inc. posted new presentation materials to its website that management plans to use periodically to discuss the company’s operations and performance with investors and other audiences. The materials were simultaneously furnished in a current report, but the company emphasized that this information is being provided for informational purposes only and is not deemed filed under federal securities laws, limiting associated legal liabilities and its automatic incorporation into future securities filings.
The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a Delaware-incorporated company, but the filing does not provide details on its industry, specific products, or market focus. Public disclosures identify it as operating under U.S. securities regulations, suggesting it is a publicly traded entity subject to Exchange Act reporting requirements.
Average Trading Volume: 102,025
Technical Sentiment Signal: Sell
Current Market Cap: $3.83M
Learn more about BIAF stock on TipRanks’ Stock Analysis page.